# US 2024/0197918 A1 · Tissue-targeted modified aav capsids and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197918 A1
- Document ID: US20240197918A1
- Status: Published application
- Kind: A1
- Application number: 18/287,963
- Filed: 2022-04-22
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Assignees: Locanabio, Inc.
- Applicants: Locanabio, Inc.
- Inventors: Greg NACHTRAB
- Web page: https://patentgrep.com/patent/US20240197918A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are modified AAV capsids comprising modified AAV capsid proteins having improved transduction in muscle tissue, reduced immunogenicity, reduced neutralizing antibody binding, reduced liver tissue transduction, and combinations thereof. Also provided are methods of treating a patient with AAV viral vectors comprising modified AAV capsid proteins.

## Claims

### Claim 1

A modified AAV capsid protein comprising a modified variable region (VR) VIII.

### Claim 2 (depends on 1)

The modified AAV capsid protein of claim 1, wherein the capsid protein is a VP1, VP2, or VP3 capsid protein.

### Claim 3 (depends on 1)

The modified AAV capsid protein of claim 1, wherein the modified VR VIII comprises a peptide insertion.

### Claim 4 (depends on 3)

The modified AAV capsid protein of claim 3, wherein the peptide insertion comprises an RGD-motif peptide insertion.

### Claim 5 (depends on 4)

The modified AAV capsid protein of claim 4, wherein the RGD-motif insertion comprises RGDLGLS (SEQ ID NO: 303), RGDLSTP (SEQ ID NO: 304), SNSRGDYNSL (SEQ ID NO: 305), ENRRGDFNNT (SEQ ID NO: 306), SRGDYNSL (SEQ ID NO: 307), RGDYNSL (SEQ ID NO: 308), RGDLST (SEQ ID NO: 309), or RGDYVGL (SEQ ID NO: 310).

### Claim 6 (depends on 4)

The modified AAV capsid protein of claim 4, wherein the RGD-motif insertion comprises a variable domain of camelid heavy-chain-only antibody (VHH) RGD peptide.

### Claim 7 (depends on 6)

The modified AAV capsid protein of claim 6, wherein the VHH RGD peptide comprises an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence EVQLQASGGGFVQAGGSLRLSCAVSGRGDLSTPSYGMHWVRQAPGKEREFVAGISR GDYNSLYYADSVQGRFTISRDNAKNTVYLQMNSLKPEDTATYYCAENRRGDFNNT YWGQGTQVTVSS (SEQ ID NO: 316).

### Claim 8 (depends on 3)

The modified AAV capsid protein of claim 3, wherein the peptide insertion comprises an acetylcholinesterase collagenic tail (ColQ) peptide.

### Claim 9 (depends on 8)

The modified AAV capsid protein of claim 8, wherein the ColQ peptide comprises an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence TPFYPVGYTVKQPGTCGDGVLQPGEECDDGNPDVSDGCIDCHRAYCGDGYRHQGV EDCDGSDFGYLTCETYLPGSYGDLRCTQYCSIDSTPCRYFT (SEQ ID NO: 302).

### Claim 10 (depends on 3)

The modified AAV capsid protein of claim 3, wherein the peptide insertion comprises one or more linker sequences at the N-terminus or C-terminus of the inserted peptide.

### Claim 11 (depends on 8)

The modified AAV capsid protein of claim 8, wherein the linker sequence comprises GGGGS (SEQ ID NO: 311), GGGGSGGGGS (SEQ ID NO: 312); GGGGSGGGGSGGGGS(SEQ ID NO: 313); GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 314); or GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 315).

### Claim 12 (depends on 1)

The modified AAV capsid protein of claim 1, wherein the AAV serotype is AAV9 or AAVRh74.

### Claim 13 (depends on 1)

The modified AAV capsid protein of claim 1, further comprising one or more amino acid mutations.

### Claim 14 (depends on 13)

The modified AAV capsid protein of claim 13, wherein the one or more amino acid mutations reduce liver transduction.

### Claim 15 (depends on 13)

The modified AAV capsid protein of claim 13, wherein the mutations comprise:
i) at least one of F503I, G507I, Y707C, and/or Y708C of Rh74, or
ii) N498I of AAV9.

### Claim 16

The modified AAV capsid protein of any one of the preceding claims, wherein the capsid protein comprises an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 53, 75, 102, 124, 245, 249, 255, 258, 262, or 267.

### Claim 17

A modified AAV capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 53, 75, 102, 124, 245, 249, 255, 258, 262, or 267.

### Claim 18 (depends on 17)

The modified AAV capsid protein of claim 17, wherein the capsid protein is encoded by a nucleic acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 151, 173, 199, 221, 270, 274, 280, 283, 287, or 292.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An AAV capsid comprising one or more AAV capsid proteins according to any one of claims 1-18.

### Claim 20 (depends on 19)

The AAV capsid of claim 19, wherein the AAV capsid has enhanced transduction in a targeted tissue or cell type relative to other tissue or cell types.

### Claim 21 (depends on 20)

The AAV capsid of claim 20, wherein the targeted tissue type is muscular tissue or muscle cells.

### Claim 22 (depends on 20)

The AAV capsid of claim 20, wherein the AAV capsid has enhanced transduction in muscle tissue.

### Claim 23 (depends on 19)

The AAV capsid of claim 19, wherein the AAV capsid has reduced transduction in non-targeted tissues or cell types.

### Claim 24 (depends on 23)

The AAV capsid of claim 23, wherein the non-targeted tissues include liver, lung, kidney, brain, spleen, intestine, spinal cord, or reproductive organs.

### Claim 25 (depends on 19)

The AAV capsid of claim 19, wherein the transduction in muscle tissue is enhanced by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 100%, about 200%, or about 300% compared the parental and/or unmodified AAV capsid.

### Claim 26 (depends on 19)

The AAV capsid of claim 19, wherein the capsid comprises:
i) a VP1 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 53; and
ii) a VP2/VP3 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 102.

### Claim 27 (depends on 19)

The AAV capsid of claim 19, wherein the capsid comprises:
i) a VP1 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 75; and
ii) a VP2/VP3 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 124.

### Claim 28 (depends on 19)

The AAV capsid of claim 19, wherein the capsid comprises:
i) a VP1 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 245; and
ii) a VP2/VP3 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 258.

### Claim 29 (depends on 19)

The AAV capsid of claim 19, wherein the capsid comprises:
i) a VP1 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 249; and
ii) a VP2/VP3 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 262.

### Claim 30 (depends on 19)

The AAV capsid of claim 19, wherein the capsid comprises:
i) a VP1 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 255; and
ii) a VP2/VP3 capsid protein comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 267.

### Claim 31 (depends on 1)

A vector comprising a nucleic acid sequence encoding a modified AAV capsid protein of claim 1.

### Claim 32 (depends on 31)

The vector of claim 31, wherein the nucleic acid sequence encoding a modified AAV capsid protein is operably linked to regulatory element that controls expression of the capsid protein in a host cell.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An AAV viral vector comprising the modified capsid protein of any one of claims 1-18 or the AAV capsid of claim 18.

### Claim 34 (depends on 33)

The AAV viral vector of claim 33, wherein the AAV viral vector comprises a recombinant AAV (rAAV) vector encoding a therapeutic transgene or nucleotide sequence of interest (NOI).

### Claim 35 (depends on 31, 33)

A cell comprising the vector of claim 31 or the AAV viral vector of claim 33.

### Claim 36 (depends on 33)

A pharmaceutical composition comprising the AAV viral vector of claim 33 and at least one pharmaceutically acceptable excipient and/or additive.

### Claim 37 (depends on 33, 36)

A method of providing a therapeutic transgene or protein to a subject, comprising administering to the subject the AAV viral vector of claim 33 or the pharmaceutical composition of claim 36.

### Claim 38 (depends on 33, 36)

A method of treating a subject having a disease and/or disorder, the method comprising administering to the subject at least one therapeutically effective amount of the AAV viral vector of claim 33 or the pharmaceutical composition of claim 36.

### Claim 39 (depends on 38)

The method of claim 38, wherein the disease and/or disorder is a muscular and/or neuromuscular disorder.

### Claim 40 (depends on 39)

The method of claim 39, wherein the muscular and/or neuromuscular disorder is muscular dystrophy or myotonic dystrophy.

### Claim 41 (depends on 37, 38, 39, 40)

The method of any one of claims 37-40, wherein the AAV viral vector or the pharmaceutical composition is administered to the subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intra-aurally, intra-ocularly, or peri-ocularly, orally, rectally, transmucosally, inhalationally, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intranervally, intrapleurally, topically, intralymphatically, intracisternally or intranerve.
